Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference
29 August 2019 - 8:01PM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that
Jason Shandell, President, and Bill Peters, CFO, will be presenting
at the Wells Fargo 2019 Healthcare Conference on Thursday,
September 5, 2019 at 3:05 p.m. Eastern Time, Boston, MA.
This presentation will be made available with a
live webcast and may be accessed by visiting Amphastar’s
Pharmaceuticals website at http://ir.amphastar.com. This webcast
will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses
primarily on developing, manufacturing, marketing, and selling
technically-challenging generic and proprietary injectable,
inhalation, and intranasal products. Additionally, the Company
sells insulin active pharmaceutical ingredient products. Most of
the Company’s finished products are used in hospital or urgent care
clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More
information is available at the Company’s website at
www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or
service marks of Amphastar Pharmaceuticals, Inc., including,
but not limited to Primatene®, Amphadase® and Cortrosyn®, are the
property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release and in the presentation
referenced above that are not historical are forward-looking
statements, including, among other things, statements relating to
the Company’s expectations regarding future financial performance,
backlog, sales and marketing of its products, market size and
growth, the timing of FDA filings or approvals, including the DMFs
of ANP, the timing of product launches, acquisitions and other
matters related to its pipeline of product candidates, its share
buyback program and other future events. These statements are not
historical facts but rather are based on Amphastar’s historical
performance and its current expectations, estimates, and
projections regarding Amphastar’s business, operations and other
similar or related factors. Words such as “may,” “might,” “will,”
“could,” “would,” “should,” “anticipate,” “predict,” “potential,”
“continue,” “expect,” “intend,” “plan,” “project,” “believe,”
“estimate,” and other similar or related expressions are used to
identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Amphastar’s control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Amphastar’s
filings with the Securities and Exchange Commission. You can locate
these reports through the Company’s website at
http://ir.amphastar.com and on the SEC’s website at
www.sec.gov. Amphastar undertakes no obligation to revise or
update information in this press release or the conference call
referenced above to reflect events or circumstances in the future,
even if new information becomes available or if subsequent events
cause Amphastar’s expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Apr 2024 to May 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From May 2023 to May 2024